Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.38B 10.82B 10B 9.24B 17.4B 1,189B 17.71B 119B 46.79B 582B 46.49B 45.47B 2,005B P/E 2026 *
-75.9x
P/E 2027 * 54.2x
Enterprise Value 11.85B 10.35B 9.57B 8.84B 16.65B 1,138B 16.96B 114B 44.79B 557B 44.51B 43.52B 1,919B EV / Sales 2026 *
7.92x
EV / Sales 2027 * 5.11x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+1.47%
1 week-3.25%
Current month+0.83%
1 month+10.46%
3 months+7.79%
6 months+10.95%
Current year-4.46%
1 week 450.6
Extreme 450.6
490.3
1 month 425.5
Extreme 425.5
490.3
Current year 354
Extreme 354
506.4
1 year 250.1
Extreme 250.1
523.2
3 years 112.6
Extreme 112.6
523.2
5 years 47
Extreme 47
523.2
10 years 0.26
Extreme 0.261
523.2
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%-3.25% - - 12.38B
-1.39%-6.15%+56.05%+71.53% 54.49B
+3.13%+11.16%+67.30%+94.35% 55.93B
-0.94%-6.28%+6.17%+427.61% 23.87B
-0.02%-3.30%-18.26%-15.64% 22.86B
+3.51%+7.50%+47.81%-3.33% 20B
+1.94%+0.21%+39.31%-29.41% 17.48B
+10.00%-2.06%+210.10%+370.99% 15.39B
+7.69%+4.38%+56.51%+712.88% 15.19B
-0.02%-0.53%+26.67%+190.83% 14.02B
Average +2.55%+0.34%+54.63%+202.20% 26.58B
Weighted average by Cap. +1.87%+0.47%+52.91%+157.41%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.21B 1.12B 2.1B 144B 2.14B 14.41B 5.65B 70.34B 5.62B 5.49B 242B 2.21B 1.93B 1.78B 1.65B 3.1B 212B 3.16B 21.25B 8.34B 104B 8.29B 8.1B 357B
Net income -201M -176M -162M -150M -283M -19.31B -288M -1.94B -760M -9.45B -755M -738M -32.55B 308M 269M 249M 230M 432M 29.55B 440M 2.96B 1.16B 14.47B 1.16B 1.13B 49.83B
Net Debt -529M -462M -428M -395M -744M -50.83B -757M -5.1B -2B -24.89B -1.99B -1.94B -85.71B -1.09B -957M -884M -817M -1.54B -105B -1.57B -10.55B -4.14B -51.49B -4.11B -4.02B -177B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
16/07/26 EUR 473.40 +1.26% 0
14/07/26 EUR 467.50 +0.36% 0
13/07/26 EUR 465.80 -0.34% 0
10/07/26 EUR 467.40 -3.89% 0
09/07/26 EUR 486.30 -0.55% 0
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
536.86USD
Average target price
678.71USD
Spread / Average Target
+26.42%

Quarterly revenue - Rate of surprise